Strides Pharma Science Limited (NSEI : STAR) agreed to acquire Manufacturing facility at Chestnut Ridge, New York and a basket of abbreviated new drug applications from Endo International plc (NasdaqGS : ENDP) for $24 million on August 4, 2021. As part of consideration, Strides Pharma will pay $24 million in cash, as well as certain other non-cash consideration. Under the terms of the agreements, Strides will provide Endo with certain contract manufacturing and other services on a transitional basis. Endo will also provide Strides with certain transitional services. The transaction will be financed by a combination of internal accruals and debt financing. The transaction is subject to customary closing conditions and expected to close in calendar year 2021. Greg Kramer, Raquel Alvarenga, Scott Thompson, Jack Turano; Suzie Trigg, Tony Subketkaew, Jeff Civins, Randall Colson, Ed Lebow, Matt Deffebach and Jennifer Kreick of Haynes and Boone, LLP acted as legal advisor to Strides Pharma Science Limited.

Strides Pharma Science Limited (NSEI:STAR) completed the acquisition of Manufacturing facility at Chestnut Ridge, New York and a basket of abbreviated new drug applications from Endo International plc (NasdaqGS:ENDP) on October 21, 2021.